Cell surface marker detection market seen reaching $10.81 billion by 2030

The Business Research Company says the global cell surface marker detection market will grow from $6.39 billion in 2025 to $10.81 billion by 2030, driven by precision medicine, single-cell analysis and expanding diagnostics. North America leads now, while Asia-Pacific is expected to grow fastest.

Why it matters: - Cell surface marker detection is becoming more important in cancer research, diagnostics and precision medicine. - The market’s projected rise signals growing demand for tools that identify and classify cells faster and more accurately. - The technology supports biomarker-based decisions in oncology, drug discovery and translational research.

What happened: - The Business Research Company projected the global cell surface marker detection market will grow from $6.39 billion in 2025 to $7.11 billion in 2026. - The firm said the market will reach $10.81 billion by 2030, reflecting an 11.0% CAGR from 2026 to 2030. - The report said North America held the largest market share in 2025. - The report said Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Cell surface marker detection identifies cells by proteins or carbohydrates on their membranes. - The method helps researchers and clinicians distinguish between different cell populations. - The report linked past growth to biomedical research, pharmaceutical drug discovery, flow cytometry in diagnostics, life sciences investment and laboratory automation. - The forecast points to precision medicine, single-cell analysis, translational research, AI-assisted cell analysis, advanced diagnostic labs and marker-based precision diagnostics as growth drivers. - The report highlighted wider use of high-throughput flow cytometry systems, advanced reagents and kits, automated cell analysis platforms and multiparameter cell profiling as major trends. - The report included coverage of South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company added market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated technology and trend analysis to its 2026 reports. - The company offered a free sample report at Download a free sample. - The company also provided the full report at View the full report.

Between the lines: - The forecast reflects a broader shift toward more targeted, data-rich diagnostics in oncology and biomedical research. - The emphasis on AI-assisted analysis and automation suggests buyers are looking for higher-throughput workflows, not just more testing volume. - The oncology backdrop matters because cancer incidence is rising globally, which increases pressure for better diagnostic tools. - The World Health Organization said in February 2024 that new cancer cases could exceed 35 million by 2050, up 77% from 20 million in 2022.

What's next: - The market’s growth will likely depend on how quickly labs adopt precision diagnostics, single-cell methods and automated analysis systems. - Regional growth in Asia-Pacific could reshape supplier priorities and investment focus over the next several years. - Further gains may follow if marker-based diagnostics move more deeply into routine clinical use.

The bottom line: - Cell surface marker detection is moving from a specialized research tool to a larger clinical and commercial market, with strong growth expected through 2030.